Abstract:TIM-3 was originally identified as a negative regulator of helper T cells and is expressed on dendritic cells (DCs). Since the inhibition of TIM-3 on DCs has been suggested to enhance T cell-mediated anti-tumor immunity, we examined its expression on DCs within the tumor microenvironment (TME) in colorectal cancer (CRC) using transcriptomic data from a public database (n = 592) and immunohistochemical evaluations from our cohorts of CRC (n = 115). The expression of TIM-3 on DCs in vitro was examined by flow cytometry, while the expression of its related molecules, cGAS and STING, on immature and mature DCs was assessed by Western blotting. The expression of HAVCR2 (TIM-3) was strongly associated with the infiltration of DCs within the TME of CRC. Immunohistochemical staining of clinical tissue samples revealed that tumor-infiltrating DCs expressed TIM-3; however, their number at the tumor-invasive front significantly decreased with stage progression. TIM-3 expression was higher on immature DCs than on mature DCs from several different donors (n = 6). Western blot analyses showed that the expression of STING was higher on mature DCs than on immature DCs, which was opposite to that of TIM-3. We demonstrated that TIM-3 was highly expressed on tumor-infiltrating DCs of CRC and that its expression was higher on immature DCs than on mature DCs.

What problem does this paper attempt to address?

The paper attempts to address the issue of TIM-3 expression on dendritic cells (DCs) in colorectal cancer (CRC) and its role in the tumor microenvironment. Specifically, the researchers found through transcriptome data and immunohistochemical analysis that TIM-3 is highly expressed on tumor-infiltrating DCs in CRC, and this expression is higher on immature DCs than on mature DCs. Additionally, the study explored the relationship between TIM-3 and the cGAS-STING pathway, finding that in immature DCs, TIM-3 expression is higher while STING expression is lower. These results suggest that TIM-3 may play an important role in inhibiting anti-tumor immune responses, and thus targeting TIM-3 could become a new strategy to enhance anti-tumor immunity.

TIM-3 Expression on Dendritic Cells in Colorectal Cancer